This measure would urge the United States Food and Drug Administration to reconsider its denial of approval for generic alternatives to the epinephrine auto-injector EpiPen, would urge the Congress of the United States to investigate the impact that Mylan NV's monopoly has had on price increases for EpiPen, and would urge the Congress and the President of the United States to take action to limit the unrestrained ability of drug manufacturers to increase prices based on what the market can bear.
Enrolled and filed with the Secretary of State at 11 a.m.
Chaptered by Secretary of State. Res. Chapter 191, Statutes of 2016.
From committee: Be adopted. Ordered to third reading. (Ayes 14. Noes 0.) (August 31).
Assembly Rule 63 suspended.
Read. Adopted. (Ayes 60. Noes 0. Page 6546.) Ordered to the Senate.
In Senate. Ordered to engrossing and enrolling.
In Assembly. Held at Desk.
Read. Adopted. (Ayes 39. Noes 0. Page 5528.) Ordered to the Assembly.
From committee: Ordered to third reading.
|Bill Text Versions||Format|
|08/29/16 - Introduced|
|09/06/16 - Enrolled|
|09/09/16 - Chaptered|
|No related documents.|
Data on Open States is updated periodically throughout the day from the official website of the California State Legislature.
If you notice any inconsistencies with these official sources, feel free to file an issue.